Cited by 123Reproductive Health and ContraceptionBone health and osteoporosis researchHypothalamic control of reproductive hormones

Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density

Kaunitz, Andrew M., Darney, Philip D., Ross, Douglas, Wolter, Kevin D., Speroff, Leon·2009·Contraception

Abstract

Background A formulation of depot medroxyprogesterone acetate (DMPA) has been developed that allows subcutaneous injection (104 mg/0.65 mL; DMPA-SC) and achieves highly effective contraception with a similar tolerability profile to intramuscular DMPA (150 mg/mL; DMPA-IM).Study design This randomized, evaluator-blinded study was designed to compare efficacy, safety, and user satisfaction in women receiving DMPA-SC (n=266) or DMPA-IM (n=268) for 2 years with an option to continue for a third year. The primary objectives were to evaluate bone mineral density (BMD) changes and contraceptive efficacy after 2 years.Results A total of 225 women completed the first 2 years of this study (DMPA-SC, n=116; DMPA-IM, n=109). After 2 years of DMPA use, BMD loss was marginally smaller in the DMPA-SC group than in the DMPA-IM group at both the total hip (-3.3% and -3.6%, respectively) and lumbar spine (-4.3% and -5.0%, respectively). In those women who received DMPA during the third year, there were no statistically significant differences in BMD loss between DMPA-SC and DMPA-IM groups at the end of Year 3. Recovery of BMD was observed in the small subpopulation of women who had discontinued DMPA-SC or DMPA-IM after the second year. The 2-year treatment-failure cumulative pregnancy rate was 0% in the DMPA-SC group and 0.8% (95% confidence interval, 0.00-2.37%) in the DMPA-IM group (life-table method). Adverse events were similar in the two groups except that injection site reactions were more common in the DMPA-SC group.Conclusion DMPA-SC is an effective and well-tolerated contraceptive option, providing comparable efficacy and BMD safety to DMPA-IM.

Integrity signals

Registry

Crossref · 10.1016/j.contraception.2009.02.005

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The negative impact of DMPA on bone mineral density is reversible toward or to baseline values within two years after discontinuation.

    “reversibility of the negative impact of DMPA on BMD toward or to baseline values within two years after discontinuation has been demonstrated in numerous studies [59,61,65,68].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kaunitz, A. M., Darney, P. D., Ross, D., Wolter, K. D., & Speroff, L.
Affiliations
  • University of Florida (US)
  • San Francisco General Hospital (US)
  • Pfizer (United States) (US)
  • Oregon Health & Science University (US)
Venue
Contraception
Publisher
Elsevier BV
Published
2009-07
Volume
80
Issue
1
Pages
7-17
ISSN
0010-7824 (ISSN-L)
OpenAlex
W2142599245
Cited by
123
References
38
Citations by year
2026: 5 · 2025: 9 · 2024: 5 · 2023: 2 · 2022: 5 · 2021: 7 · 2020: 9 · 2019: 7 · 2018: 8 · 2017: 4 · 2016: 14 · 2015: 10 · 2014: 9 · 2013: 7 · 2012: 4
FWCI
7.03
Type
journal article
Language
en
Open access
closed
Locations
  • Contraception (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
Keywords
depot medroxyprogesterone acetate, subcutaneous injection, intramuscular injection, contraceptive efficacy, bone mineral density, bone loss, pregnancy rate, injection site reactions, long-acting reversible contraception, user satisfaction
MeSH terms
Adolescent, Adult, Contraceptive Agents, Female, Delayed-Action Preparations, Estradiol, Female, Humans, Injections, Intramuscular, Injections, Subcutaneous, Metrorrhagia, Pregnancy, Bone Density, Patient Satisfaction, Medroxyprogesterone Acetate, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review